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1. Introduction 
Systemic lupus erythematosus (SLE) is generally diagnosed long after the disease begins.  
This means that the cause of the disease is hard to find, buried in the past.  In the search for 
the elusive causal agents for SLE, one candidate is the immune signaling molecule, 
interferon (IFN). Interferon is a secreted signaling protein, or cytokine, which is expressed at 
higher levels in SLE patients and has been associated with incidence and severity of the 
disease. 
A combination of environmental triggers and genetic susceptibility combine to initiate SLE.  
Although there are many etiological components, they usually converge on a heightened 
state of activation for the immune system, with resultant increases in interferon production 
and interferon signaling.  That is to say that interferon could be thought of as either a 
causative agent, a result of the disease, or both. 
This chapter will discuss the basics of interferon function and how de-regulation of 
apoptosis can lead to interferon production due to immune complexes.  We will then 
discuss how the functioning of the immune system changes in someone with SLE, the genes 
which are associated with risk for SLE, and clinical manifestations of interferon in SLE.   
2. How interferon works in the context of SLE 
Interferon is a signaling protein which is secreted to activate neighboring cells in response to 
viruses or other infections.  It is a cytokine, or immune signaling molecule which allows 
communication between cells.  When a cell is infected with a virus, interferon is produced 
and secreted as a warning to other cells to prepare for an infection.  Interferons alpha (IFNǂ) 
and beta (IFNǃ) are the type I interferons, and interferon gamma (IFNǄ) is the type II 
interferon.  Most of the cells in the human body have receptors for type I IFN, whereas 
certain immune cells express the receptor for type II IFN (Su, et al., 2004).  The proteins are 
made by many different cells, but generally speaking, IFNǂ is of leukocyte origin, IFNǃ is of 
fibroblast origin, and IFNǄ is made by lymphocytes (Lucero, et al., 1982).  Other less studied 
interferons also exist, and interferons are conserved among many species.  This chapter will 
talk mostly about type I interferons, which are IFNǂ and IFNǃ.   
The main purpose of interferon is to shut down a cell before a virus can take it over, 
although it has many other jobs (Niewold, et al., 2010).  Interferon signaling leads to 
increased apoptosis, which is a normal response to control viral spread or to decrease the 
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size of a tumor (Takaoka, et al., 2003).  If one cell can undergo apoptosis before a virus can 
replicate and infect other cells, the infection is halted (Luker, et al., 2005). 
 
 
Fig. 1. Interferon protein structures.  Interferons alpha and beta, the type I interferons, have 
a common structure composed mainly of five alpha helices (shown are IFNǂ2a and IFNǃ1 
based on PDB files 1itf and 1au1, respectively).  Although the monomers of each are very 
similar in structure, the functional form of both is a dimer, and the two dimerize differently, 
IFNǂ2a along homologous surfaces and IFNǃ1 on opposing sides of the protein (Karpusas, 
et al., 1997).  IFNǄ is show in its dimerized form, with the two colors representing two 
intertwined monomers (based on PDB file 1hig).  Not shown to scale; figures drawn with 
Jmol (Jmol, 2011). 
Interferon can be produced in response to infection, other cytokines, mitogens and several 
signaling pathways.  Once produced it is secreted where it can be recognized by other cells, 
which is called paracrine signaling, or by the cell which produced it, called autocrine 
signaling.  One type of cell, the plasmacytoid dendritic cell (pDC) is a natural IFN producer, 
and is able to make very large amounts of IFNǂ (Ronnblom & Alm, 2001). 
When interferon ligates an interferon receptor, signaling pathways are activated.  Interferon 
causes an increase in the expression of both major histocompatibility complexes (MHCI and 
MHCII) for presentation of viral peptides to T cells, which can then lead to activation of 
other cells in order to kill infected cells, and remove them (Fruh & Yang, 1999).  Interferon 
also increases intracellular levels of protein kinase R (PKR) which recognizes viral nucleic 
acids and activates RNase L to degrade viral RNAs.  PKR also slows protein synthesis by 
inactivating translational initiation factors, so that viral proteins synthesis is slowed (Pindel 
& Sadler, 2011).  p53 is also activated, which is pro-apoptotic (Takaoka, 2003).  Interferons 
activate immune cells, especially natural killer cells and macrophages (Murray, 1988).  This 
activation cascade is normally “turned off” after an infection is cleared to prevent damage to 
uninfected cells.  However this activation state is not reduced to the normal levels in 
individuals with SLE, where a higher level of interferon is present (T. Kim, et al., 1987; 
Ytterberg & Schnitzer, 1982).  This higher amount of interferon is also measurable by an 
increase in the expression of interferon-stimulated genes seen in lupus patients, called the 
interferon response signature (Baechler, et al., 2003; Bennett, et al., 2003; Feng, et al., 2006). 
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This means that IFN is turned on and that it is actively affecting how other cells are 
functioning. 
 
  
Fig. 2. Cell to cell IFN signaling and its effects.  One cell produces interferon and either 
another cell (paracrine signaling) or the same cell (autocrine signaling) receives the signal.  
↑: an increase, ↓: a decrease, MHC: major histocompatibility complex, PKR: protein kinase R, 
NK: natural killer cell, MΦ: macrophage 
As a general feature of autoimmune diseases such as SLE, the immune system is in  
an “always on” state, which can lead to a breach in the body’s natural tolerance to self.  
Once this self tolerance is lost, autoimmune disease can result.  In addressing why the 
immune system generates an attack against one’s own body, the over activation of the 
immune system, including the overproduction of interferon in SLE patients is a part of this 
picture. 
3. Interferon leads to apoptosis, and the SLE-apoptosis connection 
One effect of interferon production is the release of autoantigens due to increased cell death.  
This release is normally controlled by a process called efferocytosis, or apoptotic cell 
removal, where cell debris are processed by immune cells or neighboring cells which 
remove them by phagocytosis.  Defects in apoptotic pathways have been noted  
in individuals with SLE (Gaipl, et al., 2006).  Examples of why this occurs have been studied.  
For example, in SLE patients there is an overexpression of both soluble and membrane-
bound Fas.  Fas is a receptor which when ligated signals to a cell to undergo apoptosis.   
The levels of Fas also correlate with the amount of apoptotic lymphocytes and disease 
activity of SLE (Li, et al., 2009; Sahebari, et al., 2010).  Mouse models of lupus commonly 
have genetic variations in apoptotic pathways such the Fas/Fas L pathway and interferon 
pathways. 
Mouse as well as human SLE patients make antibodies to self antigens.  This is likely 
because of over-exposure of potential autoantigens to the immune system.  This could be 
due to an increased amount of apoptosis, or a decrease in the rate of clearance of apoptotic 
debris. Apoptosis, which can be induced by interferon, is also part of the natural cycle of 
cellular growth and death.  Cells undergoing apoptosis are recognized as dead by other 
cells, so that they are cleared (Munoz, et al., 2010). 
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Fig. 3. Production of interferon can begin with defects in apoptosis.  This can be due to 
either an increase in apoptosis or a decrease in clearance of apoptotic debris.  If contents are 
released, they can form immune complexes with autoantibodies.  These immune complexes 
can cause cells to produce interferon.  Manipulating this pathway is also a common 
characteristic of mouse models of lupus. 
3.1 Mouse models allow the study of IFN and apoptosis pathways 
Mouse models have been very useful in understanding the etiology and pathogenesis of 
lupus.  Two approaches to experimental mice have been used to generate information about 
the role of interferon in lupus.  In the first approach, interferon-related genes are knocked 
out and the resulting effects on lupus are studied.  For the second, established lupus mouse 
models are studied on a molecular level for differences in interferon pathways or interferon-
related effects. These two approaches often overlap, as in cases where interferon-related 
genes are knocked out in lupus-prone mice.  Several established lupus mouse models 
include the MRL/lpr mice, NZW/NZB, and others.  These are mice that spontaneously 
develop lupus, and several of them have been investigated to understand the role of 
interferon in their pathogenesis.  Although a complete description of the mouse models for 
lupus is beyond the scope of this or any one publication, a few illustrative examples 
represent the power of these model systems. 
One mouse model that is especially relevant for the study of interferon in lupus is the 
BXSB/MpJ (BXSB) or Yaa mouse.  These mice spontaneously develop lupus-like disease in a 
sex-linked fashion because of a duplication of the Toll-like receptor 7 (TLR7) gene on the 
Y chromosome (Izui, et al., 1994).  TLR7 is responsible for inducing interferon in response to 
viral infection or autoantibody production. 
Another interesting mouse for the study of interferon is the NZB/NZW mouse.  These mice 
spontaneously develop a lupus-like autoimmune disease.  They have been used to 
investigate the role of several interferon-related molecules and cells.  For example, treating 
these mice with interferon accelerates disease in a T-cell like manner (Z. Liu, et al., 2010; 
Mathian, et al., 2005), while knocking out or inhibiting interferon-related genes slows or 
eliminates the development of lupus-like symptoms  (Jorgensen, et al., 2007; Sharma, et al., 
2005).  These mice have been used to clarify the interactions between sex hormones and 
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interferon in lupus etiology (Bynote, et al., 2008; Panchanathan, et al., 2009; Panchanathan, et 
al., 2010), and they serve as an excellent all-around model for spontaneous development of 
lupus. 
The role of several interferon-related molecules has been examined using a combination of 
mouse models.  As an example, consider the gene interferon regulatory factor five (IRF5).  
This gene is an interferon-regulating gene which will be described in section 5.2 below.  It 
was discovered that knockout of IRF5 prevents or inhibits the development of lupus in 
MRL/lpr mice, FcǄ-/- Yaa mice, and pristine-injected mice (Richez, et al., 2010; Savitsky, et 
al., 2010; Tada, et al., 2011). 
Mouse models for lupus represent a powerful and flexible mechanism for investigating the 
role of multiple aspects of lupus.  However, it must be remembered that the mutations or 
disease manifestations in these mice are not necessarily related to those seen in human 
lupus, and therefore the results observed must be interpreted with caution. 
4. A cycle of autoantibody production 
When it comes to SLE we may think of interferon production as a cycle, which begins when 
an environmental trigger, such as a viral infection, UV light damage or medical treatment 
activates the immune system to produce interferon. 
Normally B cells which produce antibodies to self-antigens undergo negative selection, 
where they receive signals to die off or become inactivated if they make antibody against a 
self-antigen.  This self-tolerance is breached in SLE (Cancro, et al., 2009), and the self-
antigens released from damaged or apoptotic cells during or after initial triggering events 
become the targets of autoantibodies.  When autoantibodies are produced, they are made by 
B cells as well as plasma cells, which are a mature differentiated form of B cells. 
 
 
Fig. 4. The altered immune response in SLE generates a cycle.  In blue is a cycle which exists 
in SLE, amplifying the amount of IFN present.  This cycle needs a trigger, but once it begins, 
it can leave the immune system in an “always on” state. 
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Autoantibodies lead to the production of interferon by forming immune complexes which 
are immunostimulatory (Ronnblom, et al., 2011).  Immune complexes are composed of 
aggregates of antibody and antigen molecules which are processed by the body.  These 
immune complexes are a main source of SLE pathology, as they obstruct small passages in 
areas of the body such as the kidneys and joints (Crispin, et al., 2010). 
Immune complexes may include the common SLE autoantigens such as RNA-containing 
protein complexes like Sm, RNPs, Ro, and La.  Having a combination of both nucleic acids 
and protein complexed with antibody means many pathways can be turned on.  For 
example, antibody can stimulate an immune cell through an Fc receptor, nucleic acids can 
stimulate cells through Toll-like receptors (TLRs), and proteins can be recognized by other 
antibodies. 
Immune cells are activated by immune complexes and the cycle continues.  Interferon 
production is instigated by immune cells which recognize part of the complex, be it the 
antibody, the antigen, or other associated molecules. 
5. SLE genetic risk screens identify genes in interferon signaling pathways 
We have looked at the disease state of SLE, and how the immune system functions 
improperly to instigate disease.  Things begin when an environmental trigger works on the 
genetic background of varying degrees of susceptibility.  Genetic susceptibility is thought to 
account for at least 20% of the risk for SLE (Deapen, et al., 1992).  To find the actual genes 
involved, studies are performed to determine the linkage or association of a variation in the 
genome to a particular disease. 
One important method is called a genome wide association study (GWAS).  These GWA 
studies genotype thousands of individuals, grouped into SLE patients and non-patients 
comparing them at thousands of single nucleotide polymorphisms (SNPs).  These studies 
reveal the genomic regions which contain disease-associated genes, because the variations 
are more common in people with the disease.  Individual genes or gene pathways are 
pinpointed, and can ultimately lead to treatment strategies.  Many genes have been 
identified that contain SNPs which confer risk to SLE. 
These studies are especially useful for diseases with unknown or complex genetic 
components.  The genome is examined for sets of single nucleotide polymorphisms (SNPs).  
When sets of SNPs are usually inherited together in a group it is called a haplotype.  When a 
haplotype is more common in the disease group than in the unaffected group, it can be 
assumed that it is associated with the disease.  Although specific genes are sometimes found 
which may predict a disease, it is more likely that the information will reveal molecular 
pathways associated with the disease.  Association of genes or pathways to diseases such as 
heart disease, asthma, diabetes and others have been found using this method (Stranger, et 
al., 2011).  The amount of effect is measured as an odds ratio (OR), which is a measure of the 
strength of association of the disease with a haplotype.  A median OR value is around 1.3, 
with some genes having much higher association ORs.  For example, one of the lupus-
associated haplotypes TREX1, has a published OR of 25 (Lee-Kirsch, et al., 2007).  In such 
cases, the genetic risk is almost certainly associated with the disease. 
An important caveat to these tests is that they answer the question, “What?” but not the 
question, “How?”  That is, they identify genetic loci which confer risk to SLE, but then 
further studies are needed to show what functional changes affect people with a risk 
haplotype.  For most of the genes, we do not know what functional role they play.  However 
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it is promising to note that the genes are within certain pathways, some of which are already 
associated with lupus. 
 
 
Fig. 5. Genome wide association studies (GWAS).  Genome-wide association studies aim to 
discover the genetic risk component of a disease by finding differences in a group with the 
disease compared to a group of unaffected control individuals. 
Several review articles have reviewed the findings of many lupus GWAS with varying 
degrees of certainty (R.R. Graham, et al., 2009; I.T.W. Harley, et al., 2009; Moser, et al., 2009; 
Rhodes & Vyse, 2008; Sebastiani & Galeazzi, 2009).  In some cases the indicated 
susceptibility genes are common in many ethnicities and populations, while others are 
specific to certain groups. The statistical significance of many of these genes is well 
established, while others are novel and need to be replicated by other groups.  An important 
finding is that most of the genes that have been identified in GWA studies can be grouped 
into several functional pathways.  We will focus on the genes in the IFN pathway and the 
pathways involving clearing of apoptotic cells and immune complexes.   
5.1 Interferon production pathways 
Intracellular signaling pathways which control interferon production include the production 
of type I interferons by interferon regulatory factors (IRFs), and the production of type II 
interferon by STAT4.  IRFs are activated by TLRs, which are extracellular or endosomal 
pattern recognition molecules. TLRs 7, 8, and 9 recognize nucleic acids and are endosomal.  
Maintaining these TLRs in the endosome instead of the cell surface is an important barrier to 
too frequent TLR activation.  Once the nucleic acids are brought into the cells through 
endocytosis, the TLRs become activated to turn on IRFs.  TLR 8 and TLR 9 have both been 
identified as lupus risk genes (Armstrong, et al., 2009; Xu, et al., 2009). 
TLRs begin a signaling cascade through a MyD88 signaling complex.  MyD88 activates 
another confirmed locus of SLE risk, the gene which encodes IL1 receptor-associated kinase 1 
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(IRAK1).  In Sle1 and Sle3 mouse models of lupus, IRAK deficiency eliminated most lupus 
symptoms (Jacob, et al., 2009), which highlights the importance of IRAK1.  Since this gene is on 
the X chromosome, it could help explain why lupus is more common among women.  The 
MyD88 complex can be affected by osteopontin (OPN). It regulates IFNǂ production in 
plasmacytoid dendritic cells, which are the body’s main IFNǂ producer cell (Cao & Liu, 2006).  
The lupus-risk variant of OPN was tied to high IFNǂ levels in certain lupus patients (Kariuki, 
et al., 2009b). 
Two interacting proteins involved in inflammation, TNFǂ-induced protein 3 (TNFAIP3) and 
TNFAIP3-interacting protein 1 (TNIP1), are also lupus risk loci (Gateva, et al., 2009; Musone, 
et al., 2008). TNFAIP3 encodes the protein A20, which abrogates NF腔B after an 
inflammatory response, and lupus-risk variants of this gene are associated with blood and 
kidney manifestations (Bates, et al., 2009). TNIP1 interacts with TNFAIP3 as well as affecting 
several other signal transduction pathways. 
Interferon regulatory factors are activated next, downstream of TLRs; they are transcription 
factors which travel to the nucleus to bind DNA to initiate transcription.  IRF5 binds to a 
sequence-specific region of DNA to induce IFN production.  It has been confirmed as a risk 
factor for SLE in among several ethnicities (Kawasaki, et al., 2008; Kelly, et al., 2008; Lee & 
Song, 2009; Reddy, et al., 2007; Shimane, et al., 2009).  There are three main genetic variants 
within IRF5, one copy number variant with either two or four copies of a 30-bp sequence, 
and two SNPs (R.R. Graham, et al., 2007b).  The rs2004640 SNP changes the first exon, 
although this exon does not encode protein.  The other SNP, rs10954213, creates an early 
polyadenylation sequence, which yields shorter more stable mRNA (D.S.C. Graham, et al., 
2007a).  Work has shown that these variants increase the amount of IFN in the presence of 
SLE autoantibodies (Niewold, et al., 2008; Salloum, et al., 2009). 
 
 
Fig. 6. Interferon production pathways are affected by lupus-risk genes.  The * represents 
genes which have been identified as having risk for lupus.  The endosomal TLRs (7, 8, and 9) 
can bind to autoantigenic nucleic acids and signal through a MyD88 complex which can be 
affected by association with osteopontin (OPN).  If it is not blocked by TNFAIP3, this 
activates an IRAK signaling complex to phosphorylate the IRF5 and IRF7 transcription 
factors to produce type I IFN.  IL-12 or IL-23 signal through Tyk2/Jak2 to activate the 
STAT4 transcription factor to produce type II IFN, commonly in T helper cells (Watford, et 
al., 2004). 
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IRF7 is associated with SLE risk by its proximity to SNPs in the IRF7/KIAA1542 locus (J.B. 
Harley, et al., 2008; Suarez-Gestal, et al., 2009).  IRF7 SNPs have been shown to lead to 
increased IFNǂ levels and alter of which autoantibodies are made (Salloum, et al., 2009). 
Signal transducer and activator of transcription 4 (STAT4) is also associated with risk for 
SLE.  It is a transcription factor which activates genes in proliferation, differentiation and 
apoptosis pathways.  Two STAT4 SNPs have been examined, rs7574865 increases sensitivity 
to IFNǂ (Kariuki, et al., 2009a), and rs3821236 causes STAT4 to be transcribed at higher 
levels and is additive with IRF5 risk loci so that when both are present, the risk to SLE is 
multiplied (Abelson, et al., 2009; Sigurdsson, et al., 2008). 
5.2 Genes associated with apoptosis and immune complexes 
Another set of risk genes can be placed into a functional group of apoptosis-associated 
genes.  As we read earlier in the chapter, defects in apoptosis can lead to the presence of 
potential autoantigens.  For example, a cell undergoes apoptosis and instead of being 
cleared by other cells, its contents are released.  The cellular contents can contain things like 
nucleic acids, RNA binding proteins, and others which are common lupus autoantigens.  If 
antibodies bind to these antigens, a complex of multiple antibodies and multiple antigens 
can aggregate.  The resultant immune complexes can be broken down through reactions 
with complement components, which are commonly found at low levels in SLE patients 
(C.C. Liu & Ahearn, 2009).  If they are not broken down, they reach areas such as the 
kidneys or joints, which can be damaged by these immune complexes.  This is how organ 
damage usually occurs in lupus patients. 
 
 
Fig. 7. Genes associated with risk for lupus in the apoptosis pathway.  The * represents 
genes which have been identified as having risk for lupus.  TNFǂ, CASP10 and IRF5 are 
pro-apoptotic whereas OPN and p21 are anti-apoptotic.  These genes all have a role in how 
much apoptosis is occurring.  Once apoptosis has transpired, the cell must be cleared.  Parts 
of apoptotic cells or immune complexes can be recognized by other cells to facilitate their 
removal.  This is aided by recognition molecules such as the complement components 
shown here. 
The problem of creating autoantibodies could stem from too much apoptosis or too little 
clearance of apoptotic debris.  Genes identified in GWA studies that could alter the amount 
of apoptosis include TNFǂ, caspase 10, IRF5, osteopontin and p21. 
TNFǂ was identified as a risk factor for lupus in certain ethnicities (Jimenez-Morales, et 
al., 2009; Lin, et al., 2009).  TNFǂ is a cytokine which is produced and secreted to signal to 
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other cells and is found at high levels in the serum of lupus patients (Davas, et al., 1999; 
Emilie, et al., 1996; Sabry, et al., 2006).  Part of its function is to induce apoptosis—when a 
cell binds TNFǂ, it activates the caspase cascade.  Caspases are proteases which are 
activated under certain conditions and are a hallmark of apoptosis.  They cleave other 
caspases as well, and the combined proteolytic activity of several different activated 
caspases breaks down cellular components as the cell prepares to die.  Caspase 10 is part 
of this cascade and is another lupus susceptibility gene (Armstrong, et al., 2009).  Caspase 
8, is activated by TNF signaling, and cleaves caspase 10, which then cleaves caspases 3 
and 7.  IRF5, as well as being a transcription factor which helps produce IFN, is also a 
tumor suppressor gene which is commonly inactivated in cancers.  This is because of 
IRF5’s pro-apoptotic function. 
Osteopontin (OPN) and p21 are also lupus risk genes, both anti-apoptotic.  OPN promotes 
proliferation, as well as prevention of death under apoptotic stimuli (Standal, et al., 2004).  A 
mimic of p21 was used in the treatment of murine lupus in the NZB/NZW mouse, and it 
was found to dramatically reduce the disease (Goulvestre, et al., 2005). 
So, there are genes which dysregulate the amount of apoptosis, and they are associated with 
risk for lupus. But this is only half of the picture; the other part is the clearance of apoptotic 
cells or immune complexes.  Several SLE susceptibility genes in this pathway have been 
identified as well.  Active SLE can be assessed when low levels of complement proteins are 
found in circulation.  Complement can function against microbes during an infection, but 
can also help to degrade immune complexes. Once attached, they can help cells recognize 
and degrade them. Other proteins function to bind apoptotic cells or immune complexes to 
facilitate their uptake by other cells. 
Integrin ǂM (ITGAM) has been convincingly associated to SLE (Nath, et al., 2008).  Risk 
variants of ITGAM have been associated with certain clinical manifestations of lupus (Kim-
Howard, et al., 2010).  It is a cell receptor which binds to OPN or to complement C3b.  C3b 
binds to apoptotic cells or immune complexes. 
SLE association with complement components C1q, C2, C4a and C4b have large OR 
values, meaning that the risk haplotypes of these genes are causing a large effect. When 
C1q is expressed at low levels it can lead to lupus, and it was shown to increase the amount 
the of IFN produced due to immune complexes (Lood, et al., 2009). Complement 
components function by binding immune complexes by the Fc region of antibody or by 
binding to other parts of apoptotic cells, which can opsonize them for easier uptake by 
other cells.  Cells can then remove the immune complex or apoptotic debris by 
endocytosis.  Receptors for the Fc region of antibody have also been implicated in SLE risk 
(Lee-Kirsch, et al., 2007).  These receptors can bind to antibody within an immune 
complex. 
Other proteins such as milk fat globule EGF factor 8 (MFG-E8) and C-reactive  
protein (CRP) can bind to apoptotic cells by recognizing phospholipids on their 
membranes.  MFG-E8 binds to phosphatidylserine, an “eat me” signal which is expressed 
on apoptotic cells.  The MFG-E8 knockout mouse gets SLE because of failure to remove 
apoptotic cells (Yamaguchi, et al., 2010).  CRP binds to phosphocholine, which is present 
on dying or damaged cells.  Both MFG-E8 and CRP are lupus risk genes (Batuca &  
Alves, 2009; Hu, et al., 2009; H.A. Kim, et al., 2009).  Low mannose-binding lectin (MBL) 
levels can lead to higher levels of apoptosis is this lupus-risk associated gene (Pradhan,  
et al., 2010). 
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The number of genes associated with risk for SLE will likely increase, though we have an 
interesting pool of genes already that point to certain pathways associated with the disease.  
The interferon and apoptosis pathways are certainly important in SLE etiopathogenesis. 
6. Clinical component of interferon and SLE 
Many researchers have sought to determine if higher levels of IFN, which is common in 
lupus patients, is a cause of lupus or an effect of lupus.  An interesting occurrence can 
happen when someone undergoes treatment with IFNǂ.  The presence of increased levels of 
IFN leads to lupus or a lupus-like syndrome (Gota & Calabrese, 2003; Ioannou & Isenberg, 
2000; Niewold & Swedler, 2005).  Because the lupus symptoms usually disappear after IFN 
treatment ends, this connection suggests that IFN may be more of a cause than an effect.  In 
a small number of cases, some patients also develop SLE as a result of these IFN treatments.  
Furthermore, within a family, the levels of interferon among all members correlate, 
suggesting that this is a heritable trait (Niewold, et al., 2007).  That is, even the siblings of a 
lupus patient with high IFN levels are more likely to have higher IFN levels.  This also 
supports a causal role for IFN. 
Clinically, disease activity can be measured and correlated to other observations to 
determine the cause of the different levels of activity.  One item linked to SLE activity is 
interferon, where higher levels of IFN in the serum correlated with more severe disease in 
most cases (Bauer, et al., 2009; Dall'Era, et al., 2005; Feng, et al., 2006; Landolt-Marticorena, et 
al., 2009; Petri, et al., 2009; Zhuang, et al., 2005). 
Common autoantibodies also correlate with IFN levels.  A very strong correlation is 
consistently observed between IFNǂ levels and the presence of antibodies to common SLE 
autoantigens like Ro, La, Sm, RNP, and dsDNA (Kirou, et al., 2005). 
Another set of findings has to do with properties of main producer of IFNǂ, the 
plasmacytoid dendritic cells (pDCs).  High numbers of IFN-producing pDCs have been 
observed in lupus skin lesions (Blomberg, et al., 2001; Farkas, et al., 2001).  Since the cells are 
present at the scene of the crime, the increased interferon could have to do with the 
pathology in these cases. 
At the time of writing, two clinical drug trials for SLE are being conducted, Sifalimumab is 
in Phase II, and Rontalizumab is in Phase I.  Both are antibodies, designed to block 
interferon alpha signaling by binding it to prevent its recognition by neighboring cells 
(Clinical Trials, 2011).  If these drugs are found to be effective, it will show that IFN plays a 
critical role in the pathogenesis of lupus.  In addition, the United States Food and Drug 
Administration recently approved an antibody to B lymphocyte stimulator (BLyS) to treat 
SLE called Belimumab (Sanz, et al., 2011).  This should help control the selective apoptosis 
and autoantibody production to some degree.  
7. Conclusions 
Several themes have been examined in this chapter.  Specifically that the production of 
interferon is tied to lupus and that apoptosis, clearance of apoptotic cells, and the 
formation of immune complexes are events that can augment the production of interferon.  
Exciting findings about the actual genetic causes of SLE are being examined which will 
lead to better treatments for this complex disease.  Although most of the data discussed in 
this chapter are inferential, there is a large body of evidence in support of the hypothesis 
that increased interferon signaling promotes an autoimmune state in those genetically 
prone to SLE. 
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